argenx SE Sponsored ADR (ARGX)

Over the past six months, argenx SE's stock price has fluctuated, underperforming the FTSE Global All Cap Index by -4.72%. In December 2025, shares fell after the company dropped trials for an eye-disease drug. In January 2026, argenx reported preliminary full-year 2025 global product net sales of $4.15 billion. In February 2026, the company reported strong full-year 2025 financial results and positive topline results from the Phase 3 ADAPT OCULUS study of VYVGART in ocular myasthenia gravis (oMG). Wells Fargo & Company lowered their price target on argenx in February 2026. Deutsche Bank upgraded argenx to a "Buy" rating in March 2026. In March 2026, argenx SE's stock fell 3.03% amid a broader market decline, despite reporting strong Q4 earnings.

Demand for argenx SE's products, particularly VYVGART, can be subject to seasonal dynamics, with a slowdown in sales during the first quarter followed by stronger performance later in the year. This pattern was observed in 2025, with a Q1 slowdown followed by 90% full-year growth, consistent with general trends in the pharmaceutical industry.

argenx SE is a global biopharmaceutical company focused on developing antibody-based therapies for severe autoimmune diseases and cancer, utilizing its SIMPLE Antibody™ platform. Its major approved product is VYVGART (efgartigimod alfa-fcab), a first-in-class FcRn blocker, approved for generalized myasthenia gravis (gMG) in over 30 countries. A subcutaneous formulation, VYVGART Hytrulo, is also approved in the U.S., EU, UK, and Japan, and has received FDA approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). In Japan, VYVGART is approved for primary immune thrombocytopenia (ITP). The company's pipeline includes Empasiprubart in Phase 3 development for MMN and CIDP, ARGX-119 in proof-of-concept studies for CMS, ALS, and expected to start in SMA in 2025, and earlier-stage experimental medicines like ARGX-213, ARGX-124, ARGX-109, and ARGX-121. Argenx has also out-licensed candidates like ARGX-112 to LEO Pharma and ARGX-115 to AbbVie.

argenx SE is a global company with its official seat in Rotterdam, the Netherlands, and its registered office in Breda, the Netherlands. Its shares are listed on Euronext Brussels and Nasdaq. The company has operations in Europe (Belgium, Germany, France, Italy, Spain, Switzerland, and the UK), North America (U.S. and Canada), and Asia (Japan and Mainland China through a partnership with Zai Lab). VYVGART is approved in over 30 countries globally.

argenx SE maintains a positive brand reputation due to its focus on severe autoimmune diseases and the success of VYVGART. The company is viewed as an innovator committed to therapeutic breakthroughs, with a "Vision 2030" to treat 50,000 patients, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 development. The rapid commercial success of VYVGART, positive clinical trial results, achieving its first year of operating profitability in 2025, and the successful launch of the VYVGART pre-filled syringe have bolstered the company's reputation. The decision to drop trials for an eye-disease drug in December 2025 had a minor impact on reputation.

Institutional investors hold approximately 60.32% of argenx SE's stock, indicating strong professional conviction. Major institutional owners include Fmr Llc, Price T Rowe Associates Inc /md/, Janus Henderson Group Plc, Capital World Investors, Artisan Partners Limited Partnership, Avoro Capital Advisors LLC, BlackRock, Inc., Wellington Management Group Llp, Rtw Investments, Lp, Morgan Stanley, The Vanguard Group, Inc., Citadel Advisors Llc, Millennium Management LLC, and Baillie Gifford & Co. Individual ownership accounts for the remaining stake.